Levosimendan Stada

Levosimendan, the active ingredient in Levosimendan Stada, is a calcium sensitizer / inodilator presented as an intravenous solution for intravenous use. It is used to treat acute decompensated heart failure in adult patients.

GNH USA supplies Levosimendan Stada as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres and specialty clinics worldwide.

Levosimendan is indicated for conditions involving acute heart failure where enhanced cardiac contractility is required.

Acute decompensated heart failure: improves cardiac output and reduces pulmonary congestion. Post‑cardiac surgery low‑output syndrome: supports hemodynamics during early postoperative period. Chronic heart failure (bridge therapy): provides temporary inotropic support while other therapies are optimized.

Levosimendan may be associated with several adverse reactions that vary in frequency and severity.

Common Side Effects: - Hypotension: drop in blood pressure, especially during infusion. - Headache: mild to moderate intensity. - Nausea: occasional gastrointestinal upset. - Dizziness: feeling light‑headed or unsteady.

Serious or Rare Side Effects: - Ventricular arrhythmias: potentially life‑threatening rhythm disturbances. - Severe hypotension: marked blood pressure fall requiring intervention. - Myocardial ischemia: chest pain or ECG changes indicating reduced coronary perfusion. - Allergic reactions: rash, pruritus, or anaphylaxis in rare cases.

Levosimendan requires careful clinical monitoring and consideration of patient‑specific factors before and during therapy.

Hemodynamic monitoring: continuously observe blood pressure and heart rate during infusion. Renal impairment: adjust infusion rate and monitor renal function closely. Severe hepatic impairment: use with caution and consider dose modification. Concomitant vasodilators: avoid excessive hypotension by adjusting co‑administered agents. Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Levosimendan can interact with several cardiovascular agents; awareness of interaction severity guides clinical decisions.

Major Interactions (Avoid): - Sodium nitroprusside: additive vasodilation may cause severe hypotension. - Phosphodiesterase inhibitors (e.g., milrinone): synergistic inotropic effect may increase arrhythmia risk. - Beta‑blockers: may blunt the desired inotropic response.

Moderate Interactions (Monitor Closely): - ACE inhibitors: monitor blood pressure for additive hypotensive effect. - Diuretics: monitor electrolytes and volume status to prevent imbalance.